1. Home
  2. MAIA vs NINE Comparison

MAIA vs NINE Comparison

Compare MAIA & NINE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MAIA
  • NINE
  • Stock Information
  • Founded
  • MAIA 2018
  • NINE 2011
  • Country
  • MAIA United States
  • NINE United States
  • Employees
  • MAIA N/A
  • NINE N/A
  • Industry
  • MAIA Biotechnology: Pharmaceutical Preparations
  • NINE Oilfield Services/Equipment
  • Sector
  • MAIA Health Care
  • NINE Energy
  • Exchange
  • MAIA Nasdaq
  • NINE Nasdaq
  • Market Cap
  • MAIA 46.7M
  • NINE 23.8M
  • IPO Year
  • MAIA 2022
  • NINE 2018
  • Fundamental
  • Price
  • MAIA $1.88
  • NINE $0.88
  • Analyst Decision
  • MAIA
  • NINE
  • Analyst Count
  • MAIA 0
  • NINE 0
  • Target Price
  • MAIA N/A
  • NINE N/A
  • AVG Volume (30 Days)
  • MAIA 529.1K
  • NINE 8.9M
  • Earning Date
  • MAIA 08-08-2025
  • NINE 08-05-2025
  • Dividend Yield
  • MAIA N/A
  • NINE N/A
  • EPS Growth
  • MAIA N/A
  • NINE N/A
  • EPS
  • MAIA N/A
  • NINE N/A
  • Revenue
  • MAIA N/A
  • NINE $562,450,000.00
  • Revenue This Year
  • MAIA N/A
  • NINE $3.64
  • Revenue Next Year
  • MAIA N/A
  • NINE N/A
  • P/E Ratio
  • MAIA N/A
  • NINE N/A
  • Revenue Growth
  • MAIA N/A
  • NINE N/A
  • 52 Week Low
  • MAIA $1.40
  • NINE $0.44
  • 52 Week High
  • MAIA $4.24
  • NINE $2.02
  • Technical
  • Relative Strength Index (RSI)
  • MAIA 56.41
  • NINE 54.98
  • Support Level
  • MAIA $1.80
  • NINE $0.85
  • Resistance Level
  • MAIA $2.15
  • NINE $1.05
  • Average True Range (ATR)
  • MAIA 0.13
  • NINE 0.14
  • MACD
  • MAIA 0.02
  • NINE 0.00
  • Stochastic Oscillator
  • MAIA 60.00
  • NINE 21.80

About MAIA MAIA Biotechnology Inc.

MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.

About NINE Nine Energy Service Inc.

Nine Energy Service Inc is a North American onshore completion and production services provider. It targets unconventional oil and gas resource development. It operates in one segment, Completion Solutions. The Completion Solutions segment offers cementing services; completion tools, including liner hangers and accessories, frac sleeves, fully composite frac plugs, and specialty open hole float equipment and centralizers and other services. It operates in the U.S, Canada, and other countries where majority of the revenue is generated from the United States.

Share on Social Networks: